Infectious disease
EmpowerDX, a Eurofins subsidiary, just launched its direct-to-consumer COVID-19 Home Collection Kit in the U.S. through Amazon, making it one of a miniscule number of at-home and over-the-counter kits that are putting detection of the SARS-CoV-2 virus in the hands of patients.
Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
This morning, the World Health Organization issued a statement that there is no reason to stop using the vaccine because, as of this time, “no causal link has been established.”
While existing vaccines are being rolled out worldwide, Novavax’s is demonstrating effectiveness in late-stage trials and the partnership of Sanofi and Translate Bio is beginning early-stage trials for their mRNA vaccine.
Some diagnostic developers are looking ahead to the time when COVID-19 is endemic throughout the population and most people are vaccinated. From a public health perspective, COVID-19 will be treated like the seasonal flu.
Patients in a Phase II trial have begun receiving Moderna’s vaccine against the SARS-CoV-2 variant first identified in South Africa, the company announced.
Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy.
Topline results from a trial in Brazil show that treatment with Kintor’s proxalutamide cut mortality risk by 92% and significantly shortened the median length of hospital stay by nine days compared with standard of care in hospitalized patients with COVID-19.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES